Table 1.
Tumor treatment by targeting TAMs.
| Tumor type/Cell line | Treatment of TAMs or tumor-bearing mice | Effect | References |
|---|---|---|---|
| NSCLC | Hydroxychloroquine (HCQ) | CD8+ T cell infiltration↑ Anti-tumor CD8+ T cell↑ The ratio of M1/M2 (TAMs) macrophage ↑ |
(134) |
| NSCLC cell | Ginsenoside Rh2 | The expression levels of VEGF MMP2 and MMP9 ↓ The ratio of M1/M2 (TAMs) macrophage ↑ |
(135) |
| A549 | Ginsenoside Rh2 | Phosphorylation of α−catenin at S641↑Wnt and hedgehog signaling↓ E - cadherin↑ vimentin↓ Cell proliferation ↓ |
(136) |
| NSCLC | miR-125b | The ratio of M1/M2 (TAMs) macrophage ↑ | (137) |
| Lewis lung cancer cells |
β-Elemene | Proliferation migration and invasion↓ EMT↓ The ratio of M1/M2 (TAMs) macrophage ↑ |
(138) |
| Cisplatin-resistant A549 and H460 | dasatinib | Src CD155, and MIF↓ The ratio of M1/M2 (TAMs) macrophage ↑ |
(139) |
| A549 | Water extract of ginseng | Proliferation and migration↓ | (140) |
| Lewis lung cancer cells |
HangAmDan-B | Growth of LLCs↓ The ratio of M1/M2 (TAMs) macrophage ↑ |
(141) |
| Human and mouse lung tumors | ß-catenin knockdown in TAMs | Tumor size↓ The ratio of M1/M2 (TAMs) macrophage ↑ |
(142) |
| Lewis lung cancer | Fuzheng Sanjie recipe | IL-4, IL-13, TGF-α in serum ↓ IFN-γ in serum↑ |
(143) |
| Malignant pediatric brain tumors | Humanized anti-CD47 antibody | TAMs phagocytosis↑ Tumor growth ↓ |
(77) |
| PDAC | CpG | Tumor size↓ TAMs phagocytosis↑ TAMs numbers↑ The ratio of M1/M2 (TAMs) macrophage ↑ |
(2) |
| Ovarian cancer and breast cancer | Blockade of the CD24–Siglec-10 interaction |
Macrophages phagocytosis↑ | (78) |
| MHCIhi Tumor cells | Disruption of either MHC class I or LILRB1 | Macrophages phagocytosis↑ | (79) |
| An ex vivo tumor system | PSGL-1 antibodies | Pro-inflammatory cytokine↑ The ratio of M1/M2 (TAMs) macrophage ↑ |
(144) |
| MC38-tumor-bearing mice | TLR7/8-agonist-loaded nanoparticles | Tumor size↓ The ratio of M1/M2 (TAMs) macrophage ↑ |
(4) |
| Mice bearing TSA, MCA38, 4T1 tumors | CCL16, CpG plus anti-IL-10 receptor antibody | Tumor size↓ Metastases↓ CTL activity↑ TNF IL-12 and NO in macrophage↑ The ratio of M1/M2 (TAMs) macrophage↑ |
(145) |
| LLCs MOPC315 |
IFN-γ + TLR agonists | TNF-α, IL-12p40, IL-12p70 and NO in macrophage↑ IL-10 in macrophage↓ Macrophage tumoricidal activity↑ |
(146) |
| Early mammary cancers | Ferumoxytol | Tumor growth↓ caspase-3 of cancer cells↑ Liver and lung metastases↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(147) |
| B16F10 tumor-bearing mice | Ferumoxytol (FMT)+TLR3 agonist poly (I:C), | Tumor proliferation↓ TNF-α and iNOS in macrophage↑ Lung metastasis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(148) |
| Mouse fibrosarcoma tumor model | TLR7 ligation/TGF-β receptor I inhibition | iNOS, CD80 and MHC class II↑ TGF-β↓VEGF↓ CD4+ CD8+, CD19+ cells as well as neutrophils infiltrating the tumor↑ The ratio of M1/M2 (TAMs) macrophage↑ |
(149) |
| K1735-M2 tumor-bearing mice |
Knockout TLR4 in TAMs | TNF-α↓、VEGF↓ NF-kB activity in tumor cells↓ Tumor growth↓ |
(90) |
| MC-38 tumor-bearing mice | CB2 antagonists | Tumor progression↓ | (150) |
| C6 and GL261 glioma intracranial and subcutaneous model | Flavonoid CH625 (CYP4X1 inhibitors) | Survival↑ Tumor burden↓ Microvessel density↓ 14 15-EET-EA, VEGF and TGF-β in the TAMs↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(151) |
| NSCLC | Blockade of CCL2 | Growth of primary tumors↓ Spontaneous lung metastases↓ Activated intratumoral CD8+T Cells↑ The ratio of M1/M2 (TAMs) macrophage↑ |
(152) |
| Lewis lung cancer cells |
Luteolin | Phosphorylation of STAT6↓ Secretion of CCL2↓ Recruitment of monocytes↓ Migration of LLCs↓ |
(153) |
| 4T1 | PTEN and NHERF-1 | Secretion of CCL2↓VEGF-A↓ Migration of 4T1↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(154) |
| Human breast cancer cells | Zoledronic acid | Tumor growth↓ Secretion of CCL2 in MSC↓ Recruitment of macrophages↓ |
(155) |
| LLC and B16F10 tumors model | CSF1R inhibitors+ CXCR2 antagonist |
MDSC recruitment↓ Tumor growth↓ |
(156) |
| Breast cancer | Class IIa HDAC inhibitor (TMP95) | Tumor burden↓ pulmonary metastasis↓ Activated intratumoral CD8+T Cells↑ Vascular density↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(157) |
| Colon cancer | Antibody blockade of GM-CSF and IL-6 | Metastasis↓ Tumorigenesis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(67) |
| NSCLC | Bu Fei Decoction | Tumor growth↓ IL-10 and CD206 in TAMs↓ PD-L1 in NSCLC cells↓ |
(128) |
| NSCLC | IL-33 blockade | Tumor growth↓ Tregs in TME↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(158) |
| Glioma | Stat3 inhibition | Tumor growth↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(159) |
| Corosolic acid (CA)-containing liposomes |
IL-10↓ TNFα↑ The activation of STAT3↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(160) | |
| 4434 melanoma LL/2 carcinoma | Knockout ERK5 in TAMs | Tumor growth↓ The activation of STAT3↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(161) |
| U373 human glioblastoma | Oleanolic acid | IL-10↓ The activation of STAT3↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(162) |
| Lewis lung cancer | Resveratrol | Tumor growth↓ The activation of STAT3↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(163) |
| B16F10 | SOCS3 Knockout |
Survival time↑ The activation of STAT3↑ TNFα↓ IL-6↓ CCL8↑ Anti-tumor metastatic effect↑ |
(164) |
| Lewis lung cancer | Gefitinib | The activation of STAT6↓ Invasion and migration of LLC cells↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(165) |
| 4T1 | Knockdown STAT6 | Tumor growth and metastasis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(166) |
| Lewis lung cancer | Imatinib | The activation of STAT6↓ The migration of LLCs↓ Pulmonary metastasis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(167) |
| Colon cancer | MK2 Knockout |
Tumor growth↓ Tumor Angiogenesis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(168) |
| Ovarian cancer | Deletion of ABC transporters | Tumor progression↓ Cholesterol efflux↓ |
(56) |
| NSCLC | AXL targeting in tumor cells |
ICAM1 and ULBP1 in tumor cells↑ NK and CTL-mediated killing↑ Patient survival↑ |
(169) |
| Breast cancer, colon carcinoma, Melanoma, |
Antibody targeting of MARCO | Tumor growth and metastasis↓ Immune checkpoint therapy↑ The ratio of M1/M2 (TAMs) macrophage↑ |
(170) |
| PC14PE6 A549 |
Overexpression of surfactant protein A in tumor cells | NK cells activity↑ The ratio of M1/M2 (TAMs) macrophage↑ Lung cancer progression↓ |
(171) |
| Colorectal cancer | MFHAS1 knockdown | Tumor progression↓ Migration↓ E-cadherin↑ F-Cyclin D1 and N-cadherin↓ The activation of STAT6↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(58) |
| Lewis lung cancer | Metformin | The AMPKα1 activation↑ Metastases↓ Tumor angiogenesis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(172) |
| Lewis lung cancer | Astragaloside IV | Tumor growth and metastases↓ Survival time↑ The AMPKα activation↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(173) |
| Lewis lung cancer | Endostatin | Tumor growth and angiogenesis↓ VEGF↓ IL-6↓ IL-17 ↓ IFN-γ↑ HIF-1α↑ Infiltration of CD8+T cells↑ The ratio of M1/M2 (TAMs) macrophage↑ |
(174) |
| Lewis lung cancer | Qing-Re-Huo-Xue (QRHX) formulae | Tumor growth↓ Infiltration of TAMs↓ IL-6↓TNF-α↓Arg-1↓iNOS↑ VEGF↓CD31↓ CXCL12/CXCR4↓ JAK2/STAT3 phosphorylation↓ |
(175) |
| Lewis lung cancer | IFNγ and/or celecoxib | Tumor growth↓ MMP-2↓MMP-9↓VEGF↓ The density of microvessels↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(176) |
| Lewis lung cancer CMT167 |
Knockout cPLA2 | Infiltration of TAMs↓ Tumor growth and metastases↓ Survival time↑ IL-6↓ |
(177) |
| Lewis lung cancer | Melittin | Tumor growth↓ VEGF↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(178) |
| Lewis lung cancer | MEL-dKLA (hybrid peptide) | Tumor growth and angiogenesis↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(179) |
| CT-26 B16F10 |
RP-182 (synthetic peptide) | Tumor growth↓ Survival time↑ Antitumor activity of CD8+T cells↑ Conversion of from M2 (TAMs) macrophage into M1 |
(180) |
| B16F10 | LTF-IC | Tumor growth↓ Survival time↑ Granzyme B↑ VEGF↓ MDSC↓ Treg↓ The ratio of M1/M2 (TAMs) macrophage↑ |
(181) |
| B16F10 4T1 |
High-salt diets | Tumor growth↓ IL-12p40↑ ICAM-1↑ IFN-γ↑ TNF-α↑ IL-6↓ IL-10↓ CSF-2↓ T-cell-mediated antitumor responses↑ M-MDSCs differentiate to M1 macrophage |
(182) |
| Malignant phyllodes tumor | Maraviroc (a FDA-proved CCR5 inhibitor) | Tumor growth↓ Recruitment of monocytes↓ |
(21) |
| Lewis lung cancer | glycocalyx-mimicking nanoparticles (GNPs) | IL-12↑IL-10↓Arginase 1↓ CCL22↓ The ratio of M1/M2 (TAMs) macrophage↑ Tumor growth↓ |
(183) |
| Metastatic castration-resistant prostate cancer | Carlumab (CNTO 888) | Tumor growth= | (184) |
| Advanced pancreatic cancer | CCR2 inhibitor PF-04136309 +FOLFIRINOX chemotherapy | Infiltration of TAMs↓ IL-4↓IL-10↓ IL-13↓ TGF-β↓ CD4+T cell infiltration↑ CD8+T cell infiltration↑ Treg infiltration↓ Tumor growth↓ |
(185) |
| PDAC | CCR2 inhibitor, CXCR2 inhibitor +FOLFIRINOX chemotherapy | CD4+ T cell infiltration↑ CD8+ T cell infiltration↑ Tumor-infiltrating myeloid cells↓ Tumor growth↓ |
(186) |
| Colorectal cancer | CCR5 inhibitor | Anti-tumor repolarization of macrophages↑ IL-8↓VEGF↓ Tumor growth↓ |
(187) |